Patient preferences for triple-class–exposed relapsed or refractory multiple myeloma treatment: a discrete-choice study
Therapy decisions for patients with TCE RRMM should consider tradeoffs between efficacy, safety, and attributes related to treatment process and initial monitoring.
Authors
- James Harnett (ORCID: https://orcid.org/0000-0002-4217-0118)
- Karen Rodriguez-Lorenc
- Cooper Bussberg (ORCID: https://orcid.org/0000-0002-7854-3596)
- Lei Chi
- Sikander Ailawadhi (ORCID: https://orcid.org/0000-0002-8377-8111)
- Phani Kumar Chintakayala (ORCID: https://orcid.org/0000-0002-2526-8674)
- Glenn Scott Kroog (ORCID: https://orcid.org/0009-0000-2897-9810)
- Carol Mansfield (ORCID: https://orcid.org/0000-0002-3144-8938)
- Timothy J. Inocencio (ORCID: https://orcid.org/0000-0003-3394-4078)
- Qiufei Ma
Institutions
- Regeneron (United States) (US)
- WinnMed (US)
- Triangle (US)
- RTI Health Solutions (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-02-26
- DOI
- https://doi.org/10.1080/14796694.2025.2461430
- Citations
- 1
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- Regeneron Pharmaceuticals